Vertex Pharmaceuticals Inc. said that a potential hepatitis C treatment was safe and tolerable in a midstage study. The study involved a combination of telaprevir and VX-222 with pegylated-interferon and ribavirin.
Biogen Idec and Knopp Biosciences announced enrollment of the first patient in EMPOWER, a multi-national Phase 3 study evaluating the efficacy, safety and pharmacokinetics of dexpramipexole in patients with amyotrophic lateral sclerosis.
Researchers have built a computer model of the crowded interior of a bacterial cell that, in a test of its response to sugar in its environment, accurately simulates the behavior of living cells.
Scientists have discovered an essential protein that controls inflammation induced by tumor necrosis factor (TNF), an important part of the body’s defences against infection and a driver of cancer-associated inflammation.
Bristol-Myers Squibb Co. received some good news last week with the approval of its cancer treatment Yervoy, but at least one analyst believes the drugmaker now faces pressures that spare little room for near-term earnings momentum.
Medicare officials said that the program will pay the $93,000 cost of prostate cancer drug Provenge, an innovative therapy that typically gives men suffering from an incurable stage of the disease an extra four months to live.
Johnson & Johnson said that it is reorganizing its consumer business, including giving more attention to its McNeil Consumer Healthcare unit, which has been stung by around 20 recalls of popular over-the-counter products like Tylenol, Motrin, and Benadryl.
The clinical trial process has reached new levels of complexity. Trials are longer, more expansive, more complex in design, increasingly global, and require new types of data.
High-level software tools such as the Data Acquisition Assistant in National Instruments’ LabVIEW allow scientists and engineers to rapidly interface with hardware and reduce the time it takes to make complex measurements.
Konica Minolta Sensing Americas, Inc. announces the launch of its next generation color measurement instrument, the CM-5 Spectrophotometer, to the pharmaceutical industry at the 2011 Interphex show.
EMD Millipore announced the introduction of the Millicell µ-Migration Assay Kit. This slide-based platform can be used to visualize and measure the effects of chemoattractants on the migration of adherent cells in real time.
Merck KGaA announced the initiation of a Merck Serono Israel Bioincubator Fund, a strategic and corporate initiative targeting Israeli biotechnology start-ups.
Almac’s Diagnostics business unit announced the opening of its CLIA registered laboratory. The opening of the Almac CLIA Laboratory supports the company’s ongoing diomarker discovery and development strategy.
Protein aggregation, generally associated with Alzheimer's and mad cow disease, turns out to play a significant role in cancer. Certain mutations of p53 cause the protein to misfold in a way that the proteins start to aggregate.
A unique formulation of antioxidants taken orally before imaging with ionizing radiation minimizes cell damage. As much as a 50% reduction in DNA injury was observed after administering the formula prior to CT scans.